Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894443 | 1.00 | EGFR (0.60) | EGFRNR4A2PDGFRBPDGFRATDO2 | |
| SCHEMBL4147243 | 0.83 | EGFR (0.60) | EGFRNR4A2PDGFRBPDGFRATDO2 | |
| SCHEMBL28270347 | 0.81 | MAP4K4 (0.50) | EGFRTDO2PIK3CDPIK3CA | |
| Formaldehyde SCHEMBL28252166 | 0.79 | EGFR (0.55) | EGFRPDGFRBPDGFRATDO2FGFR4 | |
| SCHEMBL8641138 | 0.78 | EGFR (0.64) | EGFRTDO2IMPDH2FGFR4PIK3CD | |
| SCHEMBL28128185 | 0.78 | EGFR (0.46) | EGFRNR4A2PDGFRBPDGFRATDO2 | |
| SCHEMBL28049986 | 0.76 | EGFR (0.55) | EGFR | |
| SCHEMBL559901 | 0.75 | EGFR (0.60) | EGFRPDGFRBPDGFRATDO2IMPDH2 | |
| SCHEMBL277540 | 0.75 | EGFR (0.60) | EGFRTDO2IMPDH2FGFR4PIK3CD | |
| SCHEMBL21936740 | 0.75 | EGFR (0.60) | EGFRTDO2IMPDH2FGFR4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117999075-A | Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof | 吉斯莫治疗股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-113354591-B | Synthesis of alkylamino quinazoline and its antineoplastic activity | 广东湛江海洋医药研究院 | 2023-03-24 | — | — | CN | disclosed |
| CN-115124507-A | Quinazoline derivative and preparation method and application thereof | 沈阳药科大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-107216317-A | A kind of preparation method of afatinib intermediate | 上海医药工业研究院 | 2017-09-29 | — | — | CN | disclosed |
| CN-106061480-A | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-104774184-A | Alpha-cyano-alpha, beta-unsaturated amide compound and medical application thereof | UNIV CHINA PHARMA | 2015-07-15 | — | — | CN | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | EGFR 950/4885NR4A2 772/4885PDGFRB 489/4885 |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | EGFR 618/4885NR4A2 1409/4885PDGFRB 187/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | EGFR 618/4885NR4A2 1409/4885PDGFRB 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.